TP53 and cancer: The Multi-Omics approach, the mutational analysis combined with gene expression, and regulation of gene expression via DNA methylation and miRNA have shed light on the key genomic alterations leading to the acquisition of hallmarks of cancer: resisting cell death and causing genomic instability, such as 96% of the cases with TP53 mutation, 22% having BRCA1 and BRCA2 mutations, CCNE1 amplification, and promoter methylation of 168 genes in HGSOC (Hanahan and Weinberg, 2011) (Wu et al., 2019).